People

Alex Civetta

Associate

Civetta_Alex_lo

Alex Civetta has a general corporate practice in which he advises public and private companies on a broad range of significant corporate and financing transactions, with an emphasis on technology transactions, licensing and negotiation.

Mr. Civetta was previously a teaching assistant for negotiation courses at Harvard Law School, the Massachusetts Institute of Technology Sloan School of Management, and various executive education programs through the Harvard Program on Negotiation. He was also a summer associate at WilmerHale, where he worked on a broad variety of legal matters.

Previously, Mr. Civetta served as a law clerk for Americans United for Separation of Church and State. He researched and wrote on public forum law, the legislative prayer, and local government powers for the US Supreme Court case Greece v. Galloway.

Before obtaining his law degree, Mr. Civetta was a senior program manager at Technolutions, Inc., where he led implementations of the company's flagship software product at institutions across the country, advised clients on complex integration issues with their existing enterprise database systems, and developed a hiring and training process for new Technolutions employees.

Publications & News

View

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.

December 15, 2017

WilmerHale Reps Decibel Therapeutics in Strategic Collaboration With Regeneron

On November 29, 2017, Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. announced a collaboration to discover and develop new potential therapeutics to protect, repair and restore hearing.

November 29, 2017

WilmerHale Represents Akamai in Acquisition of Nominum

Akamai Technologies, Inc. announced the company completed its acquisition of Nominum, a provider of DNS-based security solutions supporting many of the world's leading carriers.

July 27, 2017

WilmerHale Represents Kala Pharmaceuticals in $103.5 Million IPO

On July 25, 2017, Kala Pharmaceuticals, Inc. announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters' exercise in full of their option to purchase an additional 900,000 shares, at the public offering price of $15.00 per share.

July 24, 2017

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Emergent BioSolutions announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million.

May 10, 2017

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

WilmerHale client Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, announced the pricing of a registered underwritten public offering of 3,902,439 shares of its common stock at a price to the public of $10.25 per share.

February 14, 2017

WilmerHale Counsels Cynosure in $1.65B Acquisition by Hologic

The WilmerHale team on the transaction was led by Hal Leibowitz and Jason Kropp and included Andrew Bonnes, Kim Wethly, Leon Greenfield, Bruce Manheim, Steve Barrett, Laura Schneider, Amy Null, Julie Hogan Rodgers, Ciara Baker, Davis Sluis, Caroline Dotolo and Alex Civetta.

December 23, 2016

WilmerHale Represents PerkinElmer in Selling Medical Imaging Business

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced its intent to sell its Medical Imaging business, a supplier of flat panel X-ray detectors that serve as components for industrial, medical and dental X-ray imaging systems, to Varian Medical Systems.

December 21, 2016

WilmerHale Represents Akamai Technologies in Acquiring Cyberfend

The WilmerHale deal team was led by Partner Hal Leibowitz and included Partner Jeffrey Hermanson and Associate Alex Civetta.

November 8, 2016

WilmerHale Reps Infinity Pharma in $28M Licensing Agreement with Verastem

The WilmerHale deal team was led by Partners Belinda Juran and Steven Singer and included Associate Alex Civetta.

Practices

Skip Navigation Links.

Education

HBX | Harvard Business School, Credential of Readiness (CORe), Business Analytics, Financial Accounting, Economics for Managers, with Honors, 2017

JD, cum laude, Harvard Law School

BA, Psychology, magna cum laude, Yale College, Phi Beta Kappa

Bar Admissions

Massachusetts

Skip Navigation Links.